Strategic collaboration deal for vaccine development

ARTES Biotech­nol­o­gy, spe­cial­ized in recom­bi­nant pro­tein pro­duc­tion and process devel­op­ment in micro­bial expres­sion sys­tems, start­ed a devel­op­ment col­lab­o­ra­tion for two vac­cines togeth­er with glob­al bio­phar­ma-ceu­ti­cal com­pa­ny Cru­cell. Cru­cell is focused on the research & devel­op­ment, pro­duc­tion and mar­ket­ing of vac­cines and anti­bod­ies against infec­tious dis­ease world­wide.

Aim of the long-term research coop­er­a­tion is a new-prod­uct devel­op­ment on the basis of ARTES’ virus like par­ti­cle (VLP) and the well-estab­lished Hansenu­la poly­mor­pha expres­sion sys­tem fit­ting to Crucell’s vac­cine port­fo­lio. The Hansenu­la sys­tem is the pre­ferred tech­nol­o­gy for afford­able mass vac­ci­na­tion and is rec­om­mend­ed by the WHO for hepati­tis B vac­ci­na­tion cam­paigns. In com­bi­na­tion, the unique yeast based VLP approach builds a new and very eco­nom­i­cal approach to low-cost mass pro­duc­tion of safe and effec­tive vac­cines.

Under the terms of the long-term research col­lab­o­ra­tion ARTES is respon­si­ble for deliv­ery of the pro­duc­tion cell lines and process­es to Cru­cell.